---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Long-term morbidity"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Long-term morbidity. Topics: Kidney failure requiring dialysis or transplantation, Cardiovascular disease, and Preeclampsia and pregnancy outcomes. 3 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Kidney failure requiring dialysis or transplantation

> “Black individuals in the US with a high-risk APOL1 genotype are also more likely to develop hypertension-attributed ESKD, lupus nephritis–attributed ESKD, FSGS, and HIV-associated nephropathy compared with Black individuals who have a low-risk APOL1 genotype (Figure).”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “Among blacks, the APOL1 high-risk genotype associated only with higher risk of ESRD in a fully adjusted analysis.”

Source: [Grams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5004654/)

<a id="topic-2.2.1.7-2"></a>

### Cardiovascular disease

> “A metanalysis showed no overall association between the presence of APOL1 risk variants and cardiovascular disease, suggesting that high-risk variants may not have a direct effect on cardiovascular disease independent from effects on kidney disease.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “There were also no significant associations between these variants and coronary heart disease, stroke, myocardial infarction, and heart failure when the conditions were considered individually. This study suggests that the APOL1 kidney-risk variants may not have a direct effect on cardiovascular disease separate from the effects of kidney disease itself.”

Source: [Grams et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6779370/)

> “There was no significant association between APOL1 genotypes and the composite CVD outcome in both unadjusted (HR=1.23; 95% CI: 0.83 to 1.81) and fully adjusted (HR=1.16; 95% CI: 0.77 to 1.76) models; however, in using an additive model, APOL1 high-risk variants were associated with increased cardiovascular mortality.”

Source: [Chen et al. (2017a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5570668/)

> “In those without diabetes mellitus, APOL1 high-risk genotypes associated with greater risk of incident composite CVD (hazard ratio, 1.67; 95% confidence interval, 1.12–2.47) compared with those with APOL1 low-risk genotypes in multivariable adjusted models. This latter association was driven by ischemic strokes (hazard ratio, 2.32; 95% confidence interval, 1.33–4.07), in particular, those related to small vessel disease (hazard ratio, 5.10; 95% confidence interval, 1.55–16.56).”

Source: [Gutiérrez et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6339526/)

<a id="topic-2.2.1.7-3"></a>

### Preeclampsia and pregnancy outcomes

> “Fetal APOL1 genotype has been associated with maternal preeclampsia in preterm infants and with altered fetal growth in term infants.41 There is a clear health disparity in the prevalence and severity of preeclampsia in Black women compared with Hispanic or White women, apparently due at least in part to having an APOL1 high-risk genotype.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Fetal APOL1 high-risk (HR) genotype was associated with preeclampsia, with odds ratios at EMC and UTHSC of 1.84 (95% CI 1.11, 2.93) and 1.92 (95% CI 1.05, 3.49), respectively. Maternal APOL1 HR genotype was not associated with preeclampsia. Mothers with the fetal APOL1 HR genotype had more cerebral or visual disturbances (63% versus 37%, p = 0.04).”

Source: [Reidy et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6128247/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
